Key Highlights

  • AerCap (NYSE:AER) raised its full-year adjusted EPS view to roughly USD 20.70 from around USD 16.80 back in July, a climb of about 23% that our own arithmetic produces.
  • Amgen (NASDAQ:AMGN) lifted its 2026 Revenue band to between USD 38.9 billion and USD 39.7 billion, along with its non-GAAP EPS band of USD 22.90 to USD 23.70.
  • Allegion (NYSE:ALLE) fixed its 2026 adjusted EPS band between USD 9.05 and USD 9.10 on October 22, and the register lists no change amount.
  • Each of the three finished at a record high on November 4, 2026, one day ahead of a wide market slide that put every peak to the test.

1. AerCap (NYSE:AER) Largest Revision

AerCap (NYSE:AER) posted the most substantial revision of the three. Third-quarter adjusted EPS reached USD 6.56, compared with USD 5.14 in the second quarter, and the aircraft lessor now projects full-year adjusted EPS near USD 20.70, leaving out fourth-quarter sale gains. The July target was about USD 16.80, meaning the outlook climbed roughly 23% within a quarter by our own arithmetic. Shares ended at a high of USD 165.72 on November 4, a 2.04% advance, but the screen P/E is still just 8.49. Deal Volume accounts for much of the raise, with 204 transactions in the quarter, among them 85 sales, which book gains when aircraft prices hold. AER repurchased 5.3 million shares as well, spending about USD 783 million. The concern is that more of the Earnings depends on sale profits, which could shrink if aircraft markets soften.

2. Amgen (NASDAQ:AMGN) Modest Band Lift

Amgen (NASDAQ:AMGN) lifted the top and bottom of its 2026 revenue forecast following third-quarter numbers on November 3, and its stock rose 3.73% to a peak USD 478.48. The revenue projection now runs from USD 38.9 billion to USD 39.7 billion, compared with the earlier USD 38.2 billion to USD 39.4 billion, while the EPS outlook now stands between USD 22.90 and USD 23.70, versus USD 22.30 and USD 23.50 before. At the midpoint the EPS band increased about 2% by our own arithmetic, a smaller move than at AerCap but off a far bigger base. Results backed the change: revenue climbed 8% to USD 10.4 billion, non-GAAP EPS rose 14% to USD 6.45, and the GAAP Operating Margin gained 9.9 points to 37.5%. Recent medicines power growth, Repatha up 37% and UPLIZNA up 191%. Older products act as the headwind, Prolia sales sliding 45%.

3. Allegion (NYSE:ALLE) Outlook Set in October

Allegion (NYSE:ALLE) finished the session at a peak of USD 192.69, a 1.76% advance on November 4. Its 2026 forecast was issued on October 22, and it called for adjusted EPS of USD 9.05 to USD 9.10, reported revenue growth of 9.5% to 10.5% and organic growth of 5.0% to 6.0%. No later revision appears in the register, and no change amount is given, which makes this the smallest guidance shift of the three and not a raise. Third-quarter revenue grew 9.6% to USD 1,172.6 million, while adjusted EPS advanced 13.0% to USD 2.60. Part of the margin reflected USD 19.9 million of Tariff refunds. Allegion's chief executive and finance chief are slated to address strategy at an industrial conference on November 12, 2026, the next occasion relevant to the outlook.

Where Things Stand

Among these three record-setting names, AerCap shows the biggest guidance shift, pushing its adjusted EPS view up about 23% to around USD 20.70 while the screen P/E sits at 8.49. Amgen's EPS band widened only about 2% at the midpoint, yet it covers a company producing USD 10.4 billion in quarterly revenue alongside a sizable late-stage pipeline. Allegion's outlook dates to October 22, carries no change amount in the register, and its margin was helped by tariff refunds. For each name the November 4, 2026 record came after the outlook was issued, so the upcoming task is to deliver against those targets.